Accendra Health (ACH) EBITDA (2009 - 2026)

Accendra Health (ACH) has 18 years of EBITDA data on file, last reported at $17.1 million in Q1 2026.

• On a quarterly basis, EBITDA fell 13.47% year-over-year to $17.1 million in Q1 2026; TTM through Mar 2026 was $24.8 million, a 112.1% increase from a year earlier, with the FY2025 full-year figure at $27.5 million, up 112.61% from the prior year.
• EBITDA for Q1 2026 stood at $17.1 million, down from $20.9 million in the prior quarter.
• Over the last five years, EBITDA for ACH reached as high as $88.7 million in Q4 2023 and fell as low as -$272.7 million in Q4 2024.
• Historically, EBITDA has averaged $6.2 million across 5 years, with a median of $19.8 million in 2025.
• Across the five-year window, EBITDA jumped 265.94% in 2023 and sank 407.29% in 2024, its largest moves.
• Year by year, EBITDA stood at -$53.5 million in 2022, then soared by 265.94% to $88.7 million in 2023, then sank by 407.29% to -$272.7 million in 2024, then soared by 107.67% to $20.9 million in 2025, then dropped by 18.1% to $17.1 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $17.1 million in Q1 2026, $20.9 million in Q4 2025, and $26.5 million in Q3 2025.